Holen Sie sich die Stockscreener-App
68.51
0.06%
-0.04
Handel nachbörslich:
68.51
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Breakout Zone: What analysts say about USB PRGCL stockJuly 2025 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Bond Watch: Can Arcellx Inc be the next market leaderJuly 2025 Sector Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Guggenheim Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $120 - 富途资讯
Arcellx to present anito-cel data at 2026 Tandem Meetings By Investing.com - Investing.com Nigeria
Legend Biotech, Arcellx rise after FDA draft guidance on multiple myeloma trials - MSN
Arcellx to present anito-cel data at 2026 Tandem Meetings - Investing.com
Arcellx study: earlier CAR T cut 5-year death risk by 48% - Stock Titan
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Arcellx Stock Is Sliding Despite Future Hopes - TipRanks
Arcellx director Lubner sells $450k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx director Lubner sells $450k in ACLX stock - Investing.com
Why (ACLX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FDA Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Shares - GuruFocus
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials - Seeking Alpha
Arcellx Stock Gains Momentum with New Buy Ratings - timothysykes.com
This Insider Has Just Sold Shares In Arcellx - simplywall.st
Assessing Arcellx (ACLX) Valuation After Strong Myeloma Data And Fresh Analyst Optimism - Sahm
Christopher Heery Sells 5,882 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (ACLX) CMO Heery Christopher sells $402,996 in stock By Investing.com - Investing.com India
Arcellx (ACLX) CMO Heery Christopher sells $402,996 in stock - Investing.com
Positioning Arcellx for a Pivotal 2026: Anito-cel’s Differentiated Safety, Best-in-Class CAR T Launch Potential, and Undervalued Entry Point - TipRanks
Arcellx CMO Heery sells $487k in shares By Investing.com - Investing.com South Africa
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Sells $487,197.87 in Stock - MarketBeat
Arcellx CMO Heery sells $487k in shares - Investing.com
Arcellx, Inc. Reports Increased Loss Amid Rising Expenses - MSN
Arcellx (ACLX) CMO Heery sells $393k in shares By Investing.com - Investing.com India
Christopher Heery Sells 6,131 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (ACLX) CMO Heery sells $393k in shares - Investing.com
How Investors May Respond To Arcellx (ACLX) ESOP Shelf Filing And Upbeat Kite Collaboration Coverage - simplywall.st
Understanding Momentum Shifts in (ACLX) - Stock Traders Daily
What technical signals suggest for Arcellx Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Pharma News: Is Arcellx Inc. stock vulnerable to regulatory risksWeekly Market Summary & AI Forecasted Stock Moves - Улправда
Why Arcellx Inc. stock could benefit from AI revolution2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - Улправда
ACLX: UBS Reaffirms Buy Rating Amid Stable Price Targets | ACLX Stock News - GuruFocus
Why Arcellx Stock Is Suddenly Catching Wall Street’s Eye - TipRanks
UBS initiates Arcellx stock coverage with Buy rating, $100 price target - Investing.com Nigeria
UBS initiates Arcellx stock coverage with Buy rating, $100 price target By Investing.com - Investing.com South Africa
Arcellx shares jump on strong multiple myeloma trial results - MSN
Arcellx, Inc. (ACLX) Stock Analysis: A Biotech Innovator With 81.71% Potential Upside - DirectorsTalk Interviews
First Week of August 21st Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset - MSN
Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital - MSN
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8% - MarketBeat
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):